Can Shire make the most of Baxalta's hemophilia meds?

Shire ($SHPG) CEO Flemming Ornskov says his own goals for cost savings, postmerger with Baxalta ($BXLT), are higher than the company's stated $500 million. But analysts are still skeptical of the deal; they're particularly worried about stepped-up competition in hemophilia with new meds hitting the market. More from FiercePharma

Read more on